In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 31, No. 7 ( 2016-07), p. 1315-1322
Abstract:
Aldo‐keto reductase family 1 member B10 (AKR1B10), a cancer‐related oxidoreductase, was recently reported to be upregulated in some chronic liver diseases. However, its relevance in hepatocellular carcinoma (HCC) development is not fully assessed, especially in patients with chronic hepatitis C virus (HCV) infection. Methods Aldo‐keto reductase family 1 member B10 expression in the liver of 550 patients with chronic HCV infection was immunohistochemically assessed and quantified. A multivariate Cox model was used to estimate the hazard ratios (HRs) of AKR1B10 expression for HCC development, and the cumulative incidence of HCC was evaluated using the Kaplan–Meier method. Results Aldo‐keto reductase family 1 member B10 expression in the patients ranged from 0% to 80%. During the median follow‐up of 3.2 years, 43 of 550 patients developed HCC. Multivariate analysis demonstrated that high AKR1B10 expression (≥6%) was an independent risk factor for HCC (HR, 6.43; 95% confidence interval, 2.90–14.25; P 〈 0.001). The 5‐year cumulative incidences of HCC were 22.8% and 2.2% in patients with high and low AKR1B10 expression, respectively ( P 〈 0.001). In subgroup analyses, the effects of high AKR1B10 expression on HCC development risk were significant over strata. In particular, HRs attributed to high AKR1B10 expression were significant in the subgroups that had been considered at a lower risk of HCC, such as in patients with younger age and mild hepatic fibrosis or those who achieved sustained virological response after interferon therapy. Conclusion Various degrees of AKR1B10 upregulation in the liver were observed in patients with chronic HCV infection, and high AKR1B10 expression could be a novel predictor of HCC.
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2016.31.issue-7
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2006782-3
Permalink
